In her abstract dated December 4, 2016, Elissa Phillip Gentry, a lawyer-economist says, “yes.” She claims successful False Claims Act settlements against pharmaceutical companies have helped relinquish inappropriate off-label prescriptions. She posits that it is legal initiatives like the False Claims Act, rather than new scientific information, that leads to increased compliance. She states:
These results suggest that FCA suits can help to spread information regarding appropriateness of off-label uses and call into question some of the expectations underlying current off-label regulation.
Nolan Auerbach & White has a long history of representing courageous whistleblowers in healthcare fraud False Claims Act actions against pharmaceutical companies and hospital systems. More information for potential whistleblowers is located on our main website.